Regeneron Pharmaceuticals Inc. buy Saftman
Start price
08.07.21
/
50%
€490.00
Target price
08.07.22
-
Performance (%)
21.00%
End price
08.07.22
€592.90
Summary
This prediction ended on 08.07.22 with a price of €592.90. The BUY prediction by Saftman finished with a performance of 21.00%. Saftman has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.506% | -3.506% | 31.240% | -16.090% |
| iShares Core DAX® | 0,79 % | 1,97 % | 13,39 % | 49,83 % |
| iShares Nasdaq 100 | 4,23 % | 4,34 % | 39,72 % | 89,76 % |
| iShares Nikkei 225® | 3,29 % | 6,99 % | 49,89 % | 64,38 % |
| iShares S&P 500 | 2,50 % | 2,76 % | 30,23 % | 64,25 % |
Comments by Saftman for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Saftman hat das Wertpapier Regeneron Pharmaceuticals Inc. in seinem Wikifolio Langfristige Aufwärtstrends gekauft.
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von Saftman gewählte maximale Laufzeit wurde überschritten